Education
About Us
Working with TipRanks
Follow Us
MDxHealth (MDXH)
NASDAQ:MDXH
MDXH Stock Chart & Stats
$3.54
-$0.10(-4.55%)
At close: 4:00 PM EST
$3.54
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$1.35 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)126.26K
Market Cap
$175.22M
Enterprise Value$219.49M
Total Cash (Recent Filing)$32.81M
Total Debt (Recent Filing)$84.01M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Feb 26, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding49,497,334
10 Day Avg. Volume142,944
30 Day Avg. Volume126,258
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.77
Price to Sales (P/S)1.28
P/FCF Ratio-5.57
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue2.17
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda-40.19
Forecast
1Y Price Target
$7.67Price Target Upside116.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition IntegrationIntegration of the ExoDx acquisition has increased test volumes and customer conversion, which can accelerate revenue growth as commercial efforts scale.
Cost Discipline And ProfitabilityOperating expense discipline combined with AEBITDA profitability and lower cash usage should expand margins and help generate sustainable positive free cash flow.
Revenue GuidanceCompany-issued revenue guidance above analyst consensus signals that the expanded product menu is gaining market traction and could support upward revisions to future estimates.
Bears Say
Product ReprioritizationDeprioritizing select products resulted in weaker sales in those categories, producing revenue shortfalls while the sales force shifts focus to higher-return offerings.
Revenue Execution RiskSales that fell short of consensus highlight execution risk and may pressure investor confidence until the sales strategy and integration fully stabilize.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $1.35 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $175.22M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Feb 26, 2026 which is in 20 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Nov 12, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.107 by -$0.053.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.13.
How many shares outstanding does MDxHealth have?
MDxHealth has 49,497,334 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.107. Following the earnings report the stock price went down -3.641%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (116.67% Upside)
$7.67 (116.67% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.30%
12-Months-Change
Fundamentals
Return on Equity
-720.01%
Trailing 12-Months
Asset Growth
-1.99%
Trailing 12-Months
Company Description
MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust revenue and volume growth, improved gross margins, and a successful acquisition of ExoDx. However, these positives were tempered by the discontinuation of the germline offering and ongoing net and operating losses. Overall, the sentiment reflects a company making strategic adjustments for future growth while managing current financial challenges.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$7.67
▲(116.67% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.24% Mutual Funds
43.48% Other Institutional Investors
55.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---